Idogen Interim Report

Claus Thestrup

Claus Thestrup

CEO, HCA Capital Sweden

Second quarter (April-June 2022)

Significant events in the second quarter

  • Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study with the IDO 8 program.
  • Idogen strengthens the organization with key competencies for the clinical development phase.

Significant events in the period

  • Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA. 
  • Idogens presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune Tolerance Summit. 
  • Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from 15 May.
  • Idogen’s rights issue raise MSEK 41 after issue costs. 
  • Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.

Significant events after the end of the period

  • Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.
  •  Idogen’s CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO
  • Idogen convene major owners for election to Board
  • Idogen invite to an Extraordinary General Shareholder Meeting on September 6
  •  No other significant events occurred after the end of the period that affected the results or financial position.

Disclaimer: HC Andersen Capital receives payment from Idogen for a DigitalIR/Corporate Visibility agreement.